All News
Remission Unlikely in RA
Dr. Marwan Bukhari (editor of Rheumatology) has written an editorial wherein he suggests that true remission is hard to achieve. He notes that "remission as a target is a noble objective that we should all aspire to but we should not chastise our practice if we do not achieve it, as more and more evidence suggests that we should consider it the ideal but not the norm."
Read ArticleTKR - One or Two at a Time?
His would-be surgeon tried mightily to talk him out of a bilateral knee replacement. At 340 pounds, the patient's BMI -- above 43 -- was a significant contraindication.
Read ArticleOlder Men Less Likely to be Assessed and Treated for Osteoporosis
A study from the University of Washington in Seattle find that men with osteoporosis were less likely to be assessed by dual-energy X-ray absorptiometry (DXA); vitamin D measurements and were less like to receive calcium/vitamin D and bisphosphonate prescriptions.
Read ArticleRheumNow Podcast - MTX vs. Etanercept in Psoriatic Arthritis (2.15.19)
Dr. Jack Cush discusses the news from the past week on RheumNow.com - including the SEAM trial, MRI guided T2T, biologics and infection, contraceptive use, ANA negative lupus, etc.
Read ArticleNo Added Benefit to MRI-Guided Therapy in Rheumatoid Arthritis
A treat-to-target (T2T) strategy to manage rheumatoid arthritis hinges on clinical metrics to optimize therapy. But investigators from Denmark have shown that using magnetic resonance imaging–guided T2T failed to improve disease activity remission rates or reduce radiographic progression.
Read ArticleDiffering Effects of Smoking and HLA-DRB1 in Seropositive Rheumatoids
Analyses from the Swedish EIRA incident rheumatoid arthritis cohort study shows that smoking and HLA-DRB1 exert differential effects on serologically defined RA subsets - but that the strongest influence was seen in double positive (CCP+, RF+) individuals.
Read ArticleBiologic High Out of Pocket Costs for Medicare Patients
Specialty tier drugs, including biologics, accounts for nearly half of all medication spending by Medicare Part D patients. High out-of-pocket costs for these patients is a major concern.
Read ArticleOpioid Use in Osteoarthritis Varies by State
A study in Arthritis & Rheumatology shows that there is substantial statewide variation in rates of treatment with long‐term opioid therapy in osteoarthritis - not fully explained by differences in access to healthcare providers, varying case‐mix, or state‐level policies.
Read ArticleUpdate on Pregnancy Management in RA
Two recent reports offer good news to rheumatoid arthritis (RA) women who are planning to become pregnant.
Read ArticleNo Difference in Oral or IV Antibiotics for Bone & Joint Infections
Research from the NEJM shows that oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first six weeks for complex orthopedic infections.
Read ArticleMultidisciplinary Recommendations for Rheumatoid Foot Problems
Approximately 90% of patients with rheumatoid arthritis (RA) have foot problems.
Read ArticleObesity Needs to be Treated in Psoriatic Arthritis
Obese patients with psoriatic arthritis (PsA) who followed a short-term, very low-energy diet showed improvements in multiple aspects of disease activity, a prospective study found.
Read ArticleDoes Seropositivity Change with Therapy?
A subanalysis of the early rheumatoid arthritis (RA) "IMPROVED" study has shown that changes in RA-autoantibody levels are not associated with disease activity or or long-term drug response, but instead reflect intensity of immunosuppression.
Read ArticleSmoking Doesn't Influence Rituximab Responses in Rheumatoid Arthritis
Alcohol, smoking and obesity have all been shown to influence the risk and activity of rheumatoid arthritis (RA) and may also influence response to therapy. This study assesssed whether smoking would influence response to rituximab (RTX) in RA.
Read ArticleRheumNow Podcast – FDA Panels Meet on Gout & OP (1.18.19)
Dr. Jack Cush reviews the news, articles and FDA Panel discussions from the past week.
Read ArticleCombo RA Treatment May Boost Risk for Serious Adverse Events
A current meta-analysis of safety and efficacy of combination bDMARD treatment in RA patients shows that combination treatments increase serious advese event (SAE) risks, and the risk for serious infections in particular.
Read ArticleRheumNow Podcast – A Grand New Year (1.4.19)
Dr. Jack Cush reviews the news and journals for the beginning of 2019. All from RheumNow.com.
Best wishes for a charmed 2019! My advice: 1. Just show up. 2. If you can, then you must do. 3. Live each day as if it twas your 1st day/last day/make or break day. 4. Teach.
2018 Rheumatology Year In Review
This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review. The top 10 list herein is rooted in what rheumatologists should know and what will likel
Read ArticleUncertain Long Term Efficacy in Trials of Knee Osteoarthritis
A systematic review and network meta-analysis of 47 randomized clinical trials in knee osteoarthritis finds uncertainty around estimates of effect size for pain scores thereby casting uncertainty over the long-term efficacy of medications for knee osteoarthritis.
Read ArticleSevere Cutaneous Sarcoid Treated with Tofacitinib
Researchers from Yale have taken a novel approach and shown benefits when using tofacitinib in severe cutaneous sarcoidosis.
Read Article